Israel’s cCAM has received US FDA approval to commence trials of its CM-24 monoclonal antibody (mAb) for the treatment of various types of cancers.  CM-24 targets CEACAM1, a novel immune checkpoint protein expressed on a variety of cancer cells.

http://finance.yahoo.com/news/ccam-biotherapeutics-receives-fda-approval-121500561.html